In Depth 11 Dec 2024
Targeting sugar molecules: Can glycobiology lead to a new era for cancer immunotherapy?
Find out more about the emerging field of glycobiology, which could potentially lead to a new type of cancer immunotherapy.
Cancer
- Latest Posts
In Depth 2 Dec 2024
The rise of cancer vaccines: A new era in immunotherapy
Delve into the expanding and diverse field of cancer vaccines with various approaches exploiting the immune system to fight tumors.
Best in Biotech 26 Nov 2024
Seven miRNA-focused companies pioneering new therapies in 2024
Delve into the field of miRNA with seven companies with miRNA-focused candidates in the pipeline in 2024, from oncology to neurodegeneration.
Harnessing antibody-drug conjugates (ADCs) in oncology: Pathways to clinical success
Discover how ADCs are advancing oncology, the regulatory challenges they face, and the promise they hold for the future of cancer treatment.
Best in Biotech 19 Nov 2024
Six bispecific antibody companies you should know about
Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.
In Depth 18 Nov 2024
What is Abcam’s founder, Jonathan Milner, up to?
Since Abcam was acquired in December 2023, its founder, Jonathan Milner has been very active. Delve into his investment strategy.
ADVERTISEMENT
ADVERTISEMENT
Best in Biotech 14 Nov 2024
8 biotech companies advancing new treatments for breast cancer in 2024
Delve into the diverse landscape of breast cancer treatment with nine biotech companies currently developing new treatments.
In Depth 5 Nov 2024
From consumer health to pure biopharma: Inside Sanofi’s strategic shift
Delve into Sanofi’s “play to win” strategy as investments are ramping up after their consumer health division’s divestment.
News and Trends 4 Nov 2024
Top biotech deals of October 2024
Discover the major biotech partnerships, collaborations and mergers and acquisitions that made headlines in October 2024.
Best in Biotech 31 Oct 2024
Five T cell engager companies you should know about
Discover five T cell engager companies that have emerged in recent times, as this class of therapeutics is set to take off.
In Depth 30 Oct 2024
Spatial Transcriptomics: A window into disease
The emerging spatial transcriptomics field is letting researchers map out gene expression in tumor and brain samples. How could this change the way we treat disease?
Best in Biotech 29 Oct 2024
GPCR therapies: Eight promising biotechs hacking the cell signaling pathway
In this article, we take a look at eight biotechs that have acquired funding in recent years to fortify their GPCR-focused pipelines.
ADVERTISEMENT
